The world's largest annual cancer research conference kicks off today in Chicago.
With more than 37,000 in attendance, the ASCO (American Society of Clinical Oncology) conference is a place where health care professionals and industry leaders alike present their latest breakthroughs.
But the stakes are also high for investors: the global market for oncology drugs reached $107B in 2015, and health care more generally has been in the center of the political spotlight.
On Friday the "Halftime Report" experts gave their top pharma picks ahead of this year's conference.
Trader disclosure: On June 3, 2016 the following stocks and commodities mentioned or intended to be mentioned on CNBC's "Halftime Report" were owned by the "Halftime Report" traders:
Josh Brown: Long AAPL, CORE, DE, DNKN, GE,LNKD, SAM, SHAK, TWTR, XLE
Jim Lebenthal: Long AAPL, BA, C, CSCO, DCO, DIS,EEQ, GAIA, GM, INTC, JCP, KMI, KMY, MPC, ORBC, PFE, QCOM, QRVO, SPLS, TIF, TRN,TWX, WGO
Stephanie Link: Long AAPL, AGN, AMZN, APC, AVGO,BAC, BG, CAT, CB, CMA, CRM, CSCO, CVX, DOW, EBAY, ESRX, GOOG, GOOGL, GS, HON, JPM, LEA, LOW, LPX, LRCX, MGM, MSFT, PF, PG, PH, PM, PPG, RTN, SLB, STI, SWK, SYF, UNH, UPS, URI, V, WBA, WBC, WFC, WHR, YUM
Jon Najarian: Long CHS, DIS, PEP. Long calls ABBV, BURL, DIS, CLEN, FB, GDX, M, MAR, MDLZ, MO, MSFT, RLYP, RTN, TIF, WFM, YHOO